Navigation Links
Atrium completes the sale of its Active Ingredients and Specialty Chemicals division
Date:5/22/2008

QUEBEC CITY, May 22 /PRNewswire-FirstCall/ - In accordance with the terms previously announced on April 4, 2008, Atrium Innovations Inc. "Atrium" (TSX: ATB) today announced that it has completed the sale of its Active Ingredients and Specialty Chemicals division for total proceeds of US$166.4 million in cash, subject to a post-closing working capital adjustment. Atrium is now a health and nutrition pure-play and the net proceeds from the transaction will provide the Company with better financial flexibility to pursue its corporate strategy.

About Atrium

Atrium Innovations Inc. is a recognized leading developer, manufacturer and marketer of science-based and professionally endorsed products for the health and nutrition industries. The Company focuses primarily on growing segments of the health and nutrition markets which are benefiting from the trends towards healthy living and the ageing of the population. Atrium markets a broad portfolio of finished products through its highly specialized sales and marketing network in more than 35 countries, primarily in North America and Europe. Atrium has over 575 employees and operates five manufacturing facilities. Additional information about Atrium is available on its Web site at http://www.atrium-innov.com.


'/>"/>
SOURCE Atrium Innovations Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Atrium Medical Receives FDA Approval for its Novel C-QUR Lite(TM) V-Patch and C-QUR Edge(TM) V-Patch
2. Atrium shows a strong financial performance for its first quarter
3. Atrium Innovations to Hold 2008 First Quarter Financial Results Conference Call and Webcast on May 6
4. Atrium Innovations to Hold 2007 Fourth Quarter and Full-Year Financial Results Conference Call and Webcast on February 29
5. Atrium Announces a Significant Increase in Revenues and Earnings for the Third Quarter of 2007
6. Atrium Innovations to Hold 2007 Third Quarter Financial Results Conference Call and Webcast on November 8
7. Atrium Innovations Announces Management Changes
8. Sangart, Inc. Completes Enrollment in Second Phase III Study of Hemospan, a Novel Oxygen Transport Agent
9. SynCo Bio Partners Completes Manufacture and Release of ActoGeniX Lead Product for Phase II Clinical Trials
10. Lilly Completes Final Phase of Its Indianapolis Biotechnology Complex
11. China-Biotics, Inc. Completes Foundation for Its New Plant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... 2016  Vermillion, Inc. (NASDAQ: VRML ), a ... the formation of the Steering Committee for its Pelvic ... --> Pelvic masses can present physicians and healthcare ... pregnancy is ruled out, pelvic masses may include cancers ... benign ovarian tumors and gastrointestinal and urinary tract masses. ...
(Date:2/11/2016)... BioPharma Selling Solutions (Spectra) is a new Contract ... experience, expertise, operational delivery and customer focus to ... in concert with industry leading commercial experts, the ... needs of its clients by providing value-based creative ... non-personal promotion. --> ...
(Date:2/11/2016)... Calif. , Feb. 11, 2016  Dovetail Genomics™ ... to its beta program for a planned metagenomic genome ... present the company,s metagenomic genome assembly method in a ... in Genome Biology & Technology conference in ... of these highly complex datasets is difficult. Using its ...
(Date:2/11/2016)... ... February 11, 2016 , ... Reichert Technologies, which has ... to pursue the highest level of accuracy and quality with the addition of ... the AR5 Refractometer. Accurate, reliable and tough enough for the most demanding ...
Breaking Biology Technology:
(Date:2/3/2016)... -- --> --> ... Identification System Market by Component (Hardware and Software), Search ... Government, Healthcare, and Transportation) and Geography - Global Forecast ... to be worth USD 8.49 Billion by 2020 at ... The transformation and technology evolution from the manual process ...
(Date:2/2/2016)... , Feb. 2, 2016 Checkpoint Inhibitors ... Rising Market Are you interested in the ... revenues for checkpoint inhibitors. Visiongain,s report gives those ... product and national level. Avoid falling behind ... progress, opportunities and revenues those emerging cancer therapies ...
(Date:2/1/2016)... , Feb. 1, 2016  Today, the first day ... announced plans to develop a first of its kind ... of IBM Watson. In the first application of ... (NYSE: IBM ), and Welltok will create a ... assessments with cognitive analytics, delivered on Welltok,s health optimization ...
Breaking Biology News(10 mins):